Cytokinetics (CYTK) Receivables (2016 - 2026)

Cytokinetics (CYTK) has reported Receivables for 11 consecutive years, with $6.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Receivables rose 239.31% year-over-year to $6.8 million; the TTM figure through Mar 2026 stood at $6.8 million (up 239.31% YoY), while the FY2025 annual figure was $17.8 million, up 6.69% from the prior year.
• Receivables fell to $6.8 million in Q1 2026 per CYTK's latest filing, from $17.8 million in the prior quarter.
• Across five years, Receivables topped out at $17.8 million in Q4 2025 and bottomed at $147000.0 in Q4 2022.
• Historically, Receivables has averaged $4.4 million across 5 years, with a median of $2.0 million in 2022.
• Annual changes were most pronounced in 2022 — Receivables plunged 99.72% — and 2024, when it jumped 1197.74%.
• Cytokinetics' Receivables stood at $147000.0 in 2022, then surged by 772.79% to $1.3 million in 2023, then surged by 1197.74% to $16.6 million in 2024, then increased by 6.69% to $17.8 million in 2025, then plunged by 61.57% to $6.8 million in 2026.
• Business Quant data shows CYTK's Receivables at $6.8 million in Q1 2026, $17.8 million in Q4 2025, and $1.8 million in Q3 2025.